Sedana Medical AB’s Interim report January-June 2024
Regulatory
Enrolment of both US clinical trials completed, on track for first results in 2H.
Sedana Medical to acquire its main supplier to take control of supply chain and reduce cost of goods
Regulatory
Sedana Medical AB (publ) announces it has today entered into an agreement to acquire Innovatif Cekal, the supplier of the company’s main product (Sedaconda ACD). The acquisition will enable better control of the supply chain and improved profitabilit…
Invitation to presentation of Sedana Medical’s interim report for the second quarter 2024
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2024 on Tuesday July 23 at 13:30 CET.
Sedana Medical completes patient recruitment for its clinical program in the US
Non-regulatory
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phas…
Report from Sedana Medical’s annual general meeting on 22 May 2024
Regulatory
Sedana Medical AB (publ)’s annual general meeting was held on Wednesday, 22 May 2024 and the main resolutions passed were the following.
Sedana Medical AB's Interim report January-March 2024
Regulatory
Off to a strong start with record sales in Q1
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Non-regulatory
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomi…
Notice of Annual General Meeting in Sedana Medical
Regulatory
The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting of shareholders to be held Wednesday, 22 May 2024. Further details on the proposals can be found in the notice convening the meeting, below. The not…
Sedana Medical publishes its Annual Report for 2023
Regulatory
Sedana Medical AB (publ) publishes its Annual Report for 2023. The Annual Report describes important events and financial information for 2023, as well as the progress the company has made on its strategic priorities during the year.
Invitation to presentation of Sedana Medical’s interim report for the first quarter 2024
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the first quarter of 2024 on Thursday April 25 at 13:30 CET.
Sedana Medical AB’s Year-end report 2023
Regulatory
Full year sales at upper end of financial guidance and an exciting year ahead
Invitation to presentation of Sedana Medical’s fourth quarter and year-end report for 2023
Non-regulatory
Sedana Medical AB (publ) plans to present its fourth quarter and year-end report for 2023 on Thursday February 15 at 13:30 CET.
Sedana Medical files submission for paediatric indication
Non-regulatory
Sedana Medical AB (publ) announces that the company has submitted a Type II variation with the aim of including the paediatric population (3-17 years) into the existing Sedaconda[®] indication for inhaled sedation of mechanically ventilated patients…
Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031
Non-regulatory
Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has issued a positive opinion regarding the compliance with the company’s Paediatric Investigation Plan. This confirms data exclusivity and market protection…
Key results of Sedana Medical’s paediatric study IsoCOMFORT published
Non-regulatory
Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study have been published in the Clinical Trials Registry EudraCT.
Sedana Medical AB’s Interim report January-September 2023
Regulatory
All-time-high Q3 sales and further steps towards ex-US profitability
Sedana Medical’s Nomination Committee established
Regulatory
According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2024 shall be composed of members appointed by the three largest shareholders as of Septe…
The SESAR investigator-initiated trial completes patient enrollment
Non-regulatory
Sedana Medical AB (publ) today announces that the enrollment of the planned 700 patients in the SESAR trial has been completed. The trial Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter Prospective Randomized Trial (SES…
Sedana Medical receives market approval in the UK
Non-regulatory
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Sedana Medical AB (publ) marketing authorization for the company’s pharmaceutical product Sedaconda[®] (isoflurane) in the United Kingdom.
Invitation to presentation of Sedana Medical’s interim report for the third quarter 2023
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the third quarter of 2023 on Thursday October 26 at 13:30 CET.